These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36688500)

  • 21. Clonal shifts in MDS - from SF3B1 to EZH2.
    Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
    Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
    [No Abstract]   [Full Text] [Related]  

  • 22. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
    Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.
    Gackowski D; Gawronski M; Kerr C; Radivoyevitch T; Zarakowska E; Starczak M; Abakir A; Ruzov A; Maciejewski JP; Olinski R
    Haematologica; 2020 May; 105(5):e213-e215. PubMed ID: 31488558
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR
    Winter S; Schneider M; Oelschlaegel U; Maggioni G; Riva E; Raddi MG; Bencini S; Peruzzi B; Choy D; Antunes Dos Reis R; Güse E; Lischer C; Vera J; Timms JA; Sompairac N; Sockel K; Poloni A; Tunger A; Della Porta MG; Santini V; Schmitz M; Platzbecker U; Kordasti S
    Leukemia; 2024 Jun; 38(6):1427-1431. PubMed ID: 38632316
    [No Abstract]   [Full Text] [Related]  

  • 26. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
    Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
    Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Molecular Pathology of Myelodysplastic Syndrome.
    Haferlach T
    Pathobiology; 2019; 86(1):24-29. PubMed ID: 29791902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts.
    Ma L; Luo Y; Jiang L; Shen D; Li J; Xu W; Mei C; Zhou X; Ren Y; Ye L; Lu C; Jie J; Tong H
    Leuk Lymphoma; 2019 May; 60(5):1179-1186. PubMed ID: 30409066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
    Xiong B; Xue M; Yu Y; Wu S; Zuo X
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
    Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
    Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts.
    Li Y; Cui R; Qin T; Xu Z; Zhang Y; Cai W; Cui W; Liu J; Li B; Xiao Z
    Br J Haematol; 2017 Sep; 178(5):813-816. PubMed ID: 27292319
    [No Abstract]   [Full Text] [Related]  

  • 33. Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation.
    Asou C; Maeda T; Ishikawa M; Okamura D; Kohri M; Takahashi N; Tsukasaki K; Sakaguchi H; Satoh T; Kayano H; Matsuda A; Asou N
    Int J Hematol; 2022 Jun; 115(6):898-901. PubMed ID: 35089531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
    Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
    Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
    Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
    J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
    Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
    Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Subtype Proposed for Myelodysplastic Syndrome.
    Am J Med Genet A; 2020 Aug; 182(8):1854-1855. PubMed ID: 33043582
    [No Abstract]   [Full Text] [Related]  

  • 39. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic mutations in SF3B1 aberrant-negative MDS-RS most commonly involved in TP53 genes.
    Li X; Xu F; Wu LY; Guo J; He Q; Zhang Z
    J Cell Mol Med; 2022 Jun; 26(12):3586-3589. PubMed ID: 35582925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.